PNEUMOCYSITIS CARINII INFECTION THERAPIES--PRECLIN EVAL

卡氏肺囊虫感染治疗 - PRECLIN 评估

• 批准号: 2658860
• 负责人: PETER D WALZER
• 金额: $ 31.32万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2658860
• 关键词: Pneumocystis carinii; antibacterial agents; chemoprevention; drug screening /evaluation; laboratory mouse; laboratory rat; nonhuman therapy evaluation; respiratory disorder chemotherapy; tissue /cell culture; Pneumocystis carinii; antibacterial agents; chemoprevention; drug screening /evaluation; laboratory mouse; laboratory rat; nonhuman therapy evaluation; respiratory disorder chemotherapy; tissue /cell culture

The overall objective of this contract is to facilitate discovery and development of therapies with potential for treatment and prophylaxis of Pneumocystis carinii pneumonia in people with AIDS. The expected performance of this contract is to quantitatively evaluate therapeutic agents for efficacy against Pneumocystis carinii pneumonia in a standardized, validated mouse model test system, to include evaluation of therapies in combination in the primary mouse model, drug evaluations in prophylaxis protocols in the primary mouse model, and evaluation of treatment therapies in a rat model. Therapeutic agents will be evaluated for activity in a standardized, reproducible and validated in vitro (culture) test system which employs intact organisms.

该合同的总体目的是促进发现和 开发具有治疗和预防潜力的疗法 患有艾滋病患者的肺囊藻carinii肺炎。 该合同的预期绩效是定量评估 针对肺炎肺炎肺炎的疗效的治疗剂 在标准化的，经过验证的鼠标模型测试系统中，包括 评估主要小鼠模型组合中的疗法， 主要小鼠模型中预防方案中的药物评估， 和评估大鼠模型中的治疗疗法。 治疗性 代理人将在标准化的可重复性中评估活性 并验证了使用完整的体外（培养）测试系统 有机体。